Breaking News Instant updates and real-time market news.

ABEO

Abeona Therapeutics

$5.00

0.1 (2.04%)

, NAVB

Navidea

$0.53

0.0039 (0.74%)

04:55
06/22/17
06/22
04:55
06/22/17
04:55

Biotechnology Innovation Organization to hold a convention

BIO International Convention is being held in San Diego, CA on June 19-22.

ABEO

Abeona Therapeutics

$5.00

0.1 (2.04%)

NAVB

Navidea

$0.53

0.0039 (0.74%)

XON

Intrexon

$23.95

0.65 (2.79%)

FBIO

Fortress Biotech

$4.79

-0.05 (-1.03%)

ADXS

Advaxis

$6.09

0.15 (2.53%)

ACRX

AcelRx

VICL

Vical

$2.47

0.05 (2.07%)

TNXP

Tonix Pharmaceuticals

$4.26

0.08 (1.91%)

  • 29

    Jun

  • 12

    Oct

ABEO Abeona Therapeutics
$5.00

0.1 (2.04%)

03/06/17
FBRC
03/06/17
NO CHANGE
FBRC
FBR sees 'prime' merger environment for biotechs under Trump
Potential tax reform and FDA policy changes under President Trump could "prime the pump" for acquisitions of clinical-stage biotech companies by Big Pharma, FBR Capital analysts led by Chris Meekins tell investors in a research note. These police moves, coupled with the repeal of some taxes associated with the Affordable Care Act, are likely to increase funds for companies looking to make acquisitions, the analysts contend. Within its coverage universe, FBR sees TESARO (TSRO), Agile Therapeutics (AGRX), Kite Pharma (KITE), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), Abeona Therapeutics (ABEO), Aurinia Pharmaceuticals (AUPH), Geron (GERN) and Genocea Biosciences (GNCA) as "primary targets for those looking to make acquisitions."
01/06/17
JEFF
01/06/17
INITIATION
Target $11
JEFF
Buy
Abeona Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Gena Wang started Abeona Therapeutics with a Buy rating and $11 price target. The analyst sees a favorable risk/reward ahead of data readouts in the first half of 2017.
09/29/16
MAXM
09/29/16
NO CHANGE
Target $14
MAXM
Buy
Abeona Therapeutics price target raised to $14 from $8 at Maxim
Maxim analyst Jason McCarthy raised Abeona's price target to $14 from $8 saying he expects multiple data points across several gene therapy programs to potentially push shares higher. The analyst said clinical development is underway in Abeona's Sanfilippo with positive data in two patients so far, and data from more patients are expected this fall. The company is also advancing a second Sanfilippo gene therapy, ABO-101, into the clinic later this year. Also, Abeona has brought on board a more advanced gene therapy from Stanford University, EB-101, to treat a rare skin disease which demonstrated positive data in five patients and has advanced to phase II, McCarthy wrote.
12/12/16
CANT
12/12/16
NO CHANGE
Target $21
CANT
Abeona short report 'factually incorrect and misleading,' says Cantor
Cantor Fitzgerald analyst Elemer Piros said the short report published on Seeking Alpha regarding Abeona Therapeutics is "factually incorrect and misleading." Abeona infuses its drug to the bloodstream, unlike Lysogene, whose failed clinical trial was conducted with a gene therapy that was directly injected into a handful of brain regions, Piros points out. Abeona also employs an AAV9 vector, which "delivers and promotes expression" in both neurons and glial cells, according to Piros, who reiterates his Buy rating and $21 price target on Abeona shares.
NAVB Navidea
$0.53

0.0039 (0.74%)

XON Intrexon
$23.95

0.65 (2.79%)

02/03/17
JMPS
02/03/17
NO CHANGE
Target $42
JMPS
Outperform
Dominion allows isobutanol option with Intrexon to expire, says JMP Securities
JMP Securities analyst Jason Butler said that Intrexon (XON) management confirmed in conversations with him yesterday after the markets closed that Dominion (D) allowed its option with Intrexon Energy Partners for isobutanol production facilities in North America to expire without opting in. While "somewhat disappointing," Butler said he remains confident that Intrexon and the IEP joint venture, which was formed with undisclosed investors that do not include Dominion, are making progress and Dominion's decision should not impact IEP's ability to continue advancing its efforts toward commercial production. He reiterates an Outperform rating and $42 price target on Intrexon shares.
01/25/17
RODM
01/25/17
DOWNGRADE
Target $7
RODM
Neutral
GenVec downgraded to Neutral from Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju downgraded GenVec (GNVC) to Neutral citing the takeover by Intrexon (XON). The analyst views the offer as "decent" and lowered his price target for GenVac shares to $7 from $15.
12/29/16
12/29/16
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst upgrades, downgrades, and initiations with this list compiled by The Fly: 1. Basic Energy (BAS) upgraded to Accumulate from Hold at Johnson Rice. 2. GameStop (GME) upgraded to Buy from Hold at Standpoint Research. 3. Anthera (ANTH) downgraded to Neutral from Buy at Citi and to Hold from Buy at Jefferies. 4. Senior Housing (SNH) initiated with an Overweight at Cantor. 5. Intrexon (XON) initiated with an Outperform at Northland with analyst Robert Breza saying valuation is compelling and its DNA analysis and engineering platform addresses a large market opportunity. The analyst views Deere's FY17 guidance as achievable. He kept an Outperform rating on the shares with a $117 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/29/16
NORL
12/29/16
INITIATION
Target $40
NORL
Outperform
Intrexon initiated with an Outperform at Northland
Northland analyst Robert Breza initiated Intrexon with an Outperform and a $40 price target saying valuation is compelling and its DNA analysis and engineering platform addresses a large market opportunity.
FBIO Fortress Biotech
$4.79

-0.05 (-1.03%)

03/22/17
JMPS
03/22/17
INITIATION
Target $11
JMPS
Outperform
Fortress Biotech initiated with an Outperform at JMP Securities
JMP Securities analyst Michael King initiated Fortress Biotech with an Outperform and an $11 price target.
10/03/16
ROTH
10/03/16
INITIATION
Target $9
ROTH
Buy
Fortress Biotech initiated with a Buy at Roth Capital
Roth Capital analyst Joseph Pantginis started Fortress Biotech with a Buy rating and $9 price target.
03/22/17
JMPS
03/22/17
INITIATION
JMPS
Outperform
Fortress Biotech initiated at JMP Securities
As noted earlier, JMP Securities started coverage of Fortress Biotech with an Outperform rating. Analyst Michael King is upbeat on the track record of the company's management and its ability to acquire drugs that will generate "substantial and diverse revenue streams." Target $11.
ADXS Advaxis
$6.09

0.15 (2.53%)

11/30/16
11/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Shutterfly (SFLY) initiated with a Buy at Aegis. 2. WageWorks (WAGE) initiated with a Buy at Chardan. 3. BorgWarner (BWA) initiated with a Buy at Jefferies. 4. Advaxis (ADXS) initiated with a Buy at Cantor. 5. Xtant (XTNT) initiated with a Buy at Aegis. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/16
CANT
11/30/16
INITIATION
Target $19
CANT
Buy
Advaxis initiated with a Buy at Cantor
Cantor analyst Mara Goldstein initiated Advaxis with a Buy and a $19 price target.
ACRX AcelRx

10/04/16
JEFF
10/04/16
NO CHANGE
Target $7
JEFF
Buy
Jefferies says physician survey bodes well for AcelRx
Jefferies analyst Hugo Ong says his firm's first Emergency Department physician survey on trends for acute pain management suggests a positive outlook for AcelRx's ARX-04. Physicians expect to use the drug, which could be available by the end of 2017, in 19% of their patients with moderate pain and 27% with severe pain in 2018, Ong tells investors in a research note. He believes the survey bodes well for ARX-04 and reiterates a Buy rating on AcelRx with a $7 price target.
09/15/16
ROTH
09/15/16
NO CHANGE
Target $15
ROTH
Buy
AcelRx price target raised to $15 from $11 at Roth Capital
VICL Vical
$2.47

0.05 (2.07%)

07/19/16
HCWC
07/19/16
INITIATION
Target $12
HCWC
Buy
Vical assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak assumed coverage of Vical with a Buy rating and $12 price target.
06/12/17
RODM
06/12/17
INITIATION
Target $9
RODM
Buy
Vical initiated assumed a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju assumed coverage of Vical with a Buy rating and $9 price target. Vical continues to trade at a market cap below the most recently reported cash position despite its "diversified pipeline of clinical-stage assets," the analyst writes.
TNXP Tonix Pharmaceuticals
$4.26

0.08 (1.91%)

09/07/16
CANT
09/07/16
DOWNGRADE
CANT
Hold
Tonix Pharmaceuticals downgraded to Hold from Buy at Cantor
Cantor analyst Chiara Russo downgraded Tonix after its TNX-102 SL drug missed its primary endpoint in a Phase 3 study of fibromyalgia patients, and the company decided to no longer pursue the fibromyalgia endpoint. Russo notes that the company now plans to pursue PTSD as the lead indication, but the analyst continue to "remain cautious" on that indication. Target to $1 from $5.
09/07/16
ROTH
09/07/16
DOWNGRADE
Target $1.25
ROTH
Neutral
Tonix Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Scott Henry downgraded Tonix Pharmaceuticals to Neutral from Buy as he re-evaluates its PTSD program given that it is now the primary lever for the shares after the company reported that Tonmya phase 3 data to treat fibromyalgia did not achieve its primary endpoint. The analyst also lowered his price target on the shares to $1.25 from $7.5.
09/07/16
OPCO
09/07/16
DOWNGRADE
OPCO
Perform
Tonix Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Tonix after its TNX-102 SL drug missed its primary endpoint in a Phase 3 study of fibromyalgia patients, and the company decided to no longer pursue the fibromyalgia endpoint.

TODAY'S FREE FLY STORIES

MTOR

Meritor

$24.35

1.77 (7.84%)

07:27
09/19/17
09/19
07:27
09/19/17
07:27
Recommendations
Meritor analyst commentary  »

Meritor price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAA

Under Armour

$17.37

-0.42 (-2.36%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Technical Analysis
Technical View: Under Armour falls, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

CAH

Cardinal Health

$67.07

-0.43 (-0.64%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Initiation
Cardinal Health initiated  »

Cardinal Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

HAS

Hasbro

$93.24

-1.6 (-1.69%)

, MAT

Mattel

$14.87

-0.99 (-6.24%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Hot Stocks
Toys"R"Us confirms filing Chapter 11 bankruptcy petitions in U.S. »

Toys"R"Us…

HAS

Hasbro

$93.24

-1.6 (-1.69%)

MAT

Mattel

$14.87

-0.99 (-6.24%)

JAKK

JAKKS Pacific

$2.85

-0.2 (-6.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

, FB

Facebook

$170.01

-1.63 (-0.95%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Recommendations
Amazon.com, Facebook, Alphabet, Alphabet Class A, Activision Blizzard, Electronic Arts, Take-Two analyst commentary  »

KeyBanc remains positive…

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

FB

Facebook

$170.01

-1.63 (-0.95%)

GOOG

Alphabet

$915.00

-5.29 (-0.57%)

GOOGL

Alphabet Class A

$929.75

-5.54 (-0.59%)

ATVI

Activision Blizzard

$64.20

-0.8 (-1.23%)

EA

Electronic Arts

$119.96

0.54 (0.45%)

TTWO

Take-Two

$100.82

0.43 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

ACDVF

Air Canada

$19.26

-0.7713 (-3.85%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Air Canada to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

XLRN

Acceleron

$39.38

-0.53 (-1.33%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Acceleron to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

BIG

Big Lots

$49.05

-0.97 (-1.94%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Big Lots to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 27

    Sep

CALD

Callidus Software

$26.05

0.55 (2.16%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Callidus Software to host analyst day »

Analyst Day to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ONB

Old National Bancorp

$16.70

0.3 (1.83%)

07:24
09/19/17
09/19
07:24
09/19/17
07:24
Upgrade
Old National Bancorp rating change  »

Old National Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABC

AmerisourceBergen

$80.67

-0.93 (-1.14%)

07:24
09/19/17
09/19
07:24
09/19/17
07:24
Initiation
AmerisourceBergen initiated  »

AmerisourceBergen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

MDGS

Medigus

$2.03

0.08 (4.10%)

07:22
09/19/17
09/19
07:22
09/19/17
07:22
Technical Analysis
Technical View: Medigus moves up sharply in early trading »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$82.60

0.1 (0.12%)

07:21
09/19/17
09/19
07:21
09/19/17
07:21
Initiation
Walgreens Boots Alliance initiated  »

Walgreens Boots Alliance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

CMG

Chipotle

$301.87

-11.22 (-3.58%)

07:21
09/19/17
09/19
07:21
09/19/17
07:21
Periodicals
Customers criticize Chipotle's 'queso' dip on social media, Reuters reports »

Shares of Chipotle are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTO

ZTO Express

$14.89

-0.18 (-1.19%)

07:20
09/19/17
09/19
07:20
09/19/17
07:20
Initiation
ZTO Express initiated  »

ZTO Express initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$16.75

0.64 (3.97%)

07:20
09/19/17
09/19
07:20
09/19/17
07:20
Hot Stocks
Synchronoss drops 12% after Siris withdraws acquisition interest »

Siris Capital Group on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$16.75

0.64 (3.97%)

07:19
09/19/17
09/19
07:19
09/19/17
07:19
Technical Analysis
Technical View: Synchronoss falls sharply after Siris drops all-cash offer »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$83.31

0.14 (0.17%)

07:18
09/19/17
09/19
07:18
09/19/17
07:18
Initiation
CVS Health initiated  »

CVS Health initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 17

    Oct

MZOR

Mazor Robotics

$46.99

2.29 (5.12%)

07:16
09/19/17
09/19
07:16
09/19/17
07:16
Hot Stocks
Migdal takes 4.92% passive stake in Mazor Robotics »

Migdal Insurance &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

THS

TreeHouse

$67.29

0.08 (0.12%)

07:15
09/19/17
09/19
07:15
09/19/17
07:15
Initiation
TreeHouse initiated  »

TreeHouse reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBC

Wabco

, MTOR

Meritor

$24.35

1.77 (7.84%)

07:15
09/19/17
09/19
07:15
09/19/17
07:15
Recommendations
Wabco, Meritor analyst commentary  »

Wabco price target raised…

WBC

Wabco

MTOR

Meritor

$24.35

1.77 (7.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAS

Americas Silver

$4.15

-0.36 (-7.98%)

07:15
09/19/17
09/19
07:15
09/19/17
07:15
Recommendations
Americas Silver analyst commentary  »

Americas Silver price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

07:15
09/19/17
09/19
07:15
09/19/17
07:15
General news
FX Update: The dollar has traded mixed »

FX Update: The dollar has…

AAPL

Apple

$158.67

-1.21 (-0.76%)

07:14
09/19/17
09/19
07:14
09/19/17
07:14
Periodicals
Apple Watch Series 3 takes 80%-90% of preorders, AI reports »

The LTE-enabled Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CERN

Cerner

$69.30

-2.18 (-3.05%)

07:13
09/19/17
09/19
07:13
09/19/17
07:13
Initiation
Cerner initiated  »

Cerner initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.